Marcus Gail Boxer, a director at Natera, Inc. (NASDAQ:NTRA), recently sold a significant portion of his holdings in the company. According to a Form 4 filing with the Securities and Exchange Commission, Boxer sold a total of 9,682 shares of common stock on November 19, 2024. The transactions were executed at prices ranging from $159.29 to $160.87 per share, amounting to a total sale value of approximately $1.55 million.
Following these transactions, Boxer retains ownership of 9,704 shares in Natera. The sales were conducted over two separate transactions, with the first involving 7,582 shares at an average price of $159.8314, and the second involving 2,100 shares at an average price of $160.5186.
In other recent news, Natera Inc (NASDAQ:NTRA). reported a substantial 64% year-over-year increase in Q3 revenue, totaling $439.8 million, exceeding expectations. This growth was partly driven by a 71% increase in sales of Signatera, Natera's cancer detection test, and a significant contribution from the Women's Health segment. The company also reported gross margins surpassing estimates by 500 basis points, and a robust free cash flow of $35 million for the quarter. Following these results, Natera revised its full-year revenue guidance upwards to between $1.61 billion and $1.64 billion.
In response to Natera's impressive financial performance, TD Cowen, Baird, and Jefferies have all shown confidence in the company. TD Cowen raised its price target from $155 to $175, Baird increased its target from $120 to $160, and Jefferies boosted its target from $142 to $182, all maintaining positive ratings.
In addition to financial achievements, Natera reported a 54% increase in oncology test volumes from the previous year and promising results from the Signatera test in predicting overall survival and chemotherapy benefits in colorectal cancer. Despite potential challenges ahead, Natera sees significant growth opportunities with over 100 trials underway. These are the latest developments in the company's ongoing progress.
InvestingPro Insights
The recent stock sale by Natera's director Marcus Gail Boxer comes at a time when the company's stock is trading near its 52-week high, as indicated by InvestingPro data. This aligns with one of the InvestingPro Tips, which notes that Natera is "Trading near 52-week high." The stock's strong performance is further evidenced by its impressive year-to-date price total return of 170.37%, showcasing significant investor confidence in the company's prospects.
Natera's financial metrics reveal a company in a growth phase, with revenue growth of 54.94% over the last twelve months as of Q3 2024. This robust top-line expansion is complemented by a healthy gross profit margin of 57.66%. However, it's worth noting that despite this growth, Natera is not yet profitable, with a negative operating income of $242.09 million for the same period.
Another InvestingPro Tip highlights that "7 analysts have revised their earnings upwards for the upcoming period," suggesting positive sentiment among market experts regarding Natera's future financial performance. This optimism is reflected in the stock's valuation, with a Price to Book ratio of 25.45, indicating that investors are willing to pay a premium for Natera's growth potential.
For investors seeking a more comprehensive analysis, InvestingPro offers 16 additional tips for Natera, providing deeper insights into the company's financial health and market position. These tips can be particularly valuable in understanding the context of insider transactions like Director Boxer's recent sale.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.